XORTX Therapeutics Inc XRTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if XRTX is a good fit for your portfolio.
News
-
XORTX Announces Publication of Key Research in ADPKD
-
XORTX Welcomes New Member to the Board of Directors
-
XORTX Announces Participation in Spring 2024 Investor Conferences
-
XORTX Announces New Clinical Advisory Board Member
-
XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
Trading Information
- Previous Close Price
- $2.90
- Day Range
- $2.77–2.84
- 52-Week Range
- $1.98–7.52
- Bid/Ask
- $2.62 / $2.77
- Market Cap
- $8.03 Mil
- Volume/Avg
- 4,805 / 53,202
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 3
- Website
- https://www.xortx.com
Valuation
|
Metric
|
XRTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
XRTX
Financial Strength
|
Metric
|
XRTX
|
|---|---|
Quick Ratio | 9.28 |
Current Ratio | 9.44 |
Interest Coverage | — |
Quick Ratio
XRTX
Profitability
|
Metric
|
XRTX
|
|---|---|
Return on Assets (Normalized) | −90.57% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −117.42% |
Return on Assets
XRTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tthcxnlpq | Lggxx | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tfwzmrp | Qmfpn | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lmhyrcjdk | Pwwbkp | $99.5 Bil | |
MRNA
| Moderna Inc | Fbwkbshv | Mbrcx | $38.8 Bil | |
ARGX
| argenx SE ADR | Nrsdxgyy | Ylzn | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Nqpmyxby | Sjck | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dvzvndbx | Rtcqbl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Psbhdnqvg | Ckbyg | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qdphgrzxy | Vkkdtx | $12.5 Bil | |
INCY
| Incyte Corp | Gnjdxvl | Glqvzm | $11.6 Bil |